Aeglea BioTherapeutics Provides Corporate Update and Reports First Quarter 2017 Financial Results

AUSTIN, Texas, May 09, 2017 (GLOBE NEWSWIRE) — Aeglea BioTherapeutics, Inc., (AGLE) a biotechnology company committed to developing enzyme-based therapeutics in the field of amino acid metabolism to treat rare genetic diseases and cancer, today provided a corporate update and reported financial results for the first quarter ended March 31, 2017.